Accueil   Diary - News   All news Adocia Expands Clinical Development to Obesity

Adocia Expands Clinical Development to Obesity

 

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

 

  • Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity treatment
  • Administering short-acting hormones by a pump empowers the patient, who can optimize the benefit/risk ratio of their treatment
  • These formulations could also be developed for the treatment of other metabolic diseases such as NASH (Non-Alcoholic Steato-Hepatitis), type 2 diabetes or neurodegenerative diseases

 

7:30 am CEST- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides announced today that three patent families have been filed for the treatment of metabolic diseases including obesity, NASH (Non-Alcoholic Steato-Hepatitis), type 2 diabetes and neurodegenerative disorders. These patents relate to combinations of short-acting hormones administered via pump. First preclinical results obtained in obese mice population by a combination of glucagon-exenatide (BioChaperone® GluExe) show a weight loss of 25% versus 15% with exenatide alone after 14 days of treatment1 . A second combination of pramlintide and exenatide (PramExe), currently in development, also presents promising properties. The pumps used are those already marketed for insulin therapy, and in particular patch-pumps, which are easy to use and suitable for this purpose. The user can adjust the maximal tolerable dose and therefore optimize the benefit/risk balance.

 

Read the press release